---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-277504"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:38:54.205687+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcellx expands Kite partnership: $85M upfront, $200M equity at $61.68/sh; cash runway to 2027

## Summary
- Kite exercises option for ARC-SparX program ACLX-001 in multiple myeloma; collaboration expanded to lymphomas for CART-ddBCMA.
- Arcellx receives $85M upfront cash; Gilead purchases 3,242,542 shares at $61.68/sh for $200M; Gilead ownership ~13%.
- Cash runway extended into 2027; transaction expected close year-end 2023, subject to HSR clearance.
- Potential milestone payments to offset prespecified development costs; operational efficiencies identified.

## SEC filing metadata
- accession: 0001193125-23-277504
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312523277504/0001193125-23-277504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312523277504/d850591d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-277504
- JSON: https://secwatch.observer/filing/0001193125-23-277504.json
- Plain text: https://secwatch.observer/filing/0001193125-23-277504.txt

## Key facts
- Material Agreements
  Arcellx, Inc. entered into 2023 Purchase Agreement with Gilead Sciences, Inc. valued at $200 million (effective 2023-11-15).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Gilead Sciences, Inc.
  - Value: $200 million
  - Effective: 2023-11-15
  source text: entered into a common stock purchase agreement (the "2023 Purchase Agreement") with Gilead Sciences, Inc. ("Gilead") on November 15, 2023, pursuant to which Arcellx agreed to issue and sell, and Gilead has agreed to purchase, 3,242,542 shares of Arcellx's common stock (the "Shares") for an aggregate purchase price of $200 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000119312523277504/0001193125-23-277504-index.htm
- Material Agreements
  Arcellx, Inc. amended License Amendment with Kite Pharma, Inc., a Gilead Company valued at $85 million (effective 2023-11-15).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Kite Pharma, Inc., a Gilead Company
  - Value: $85 million
  - Effective: 2023-11-15
  source text: entered into an amendment (the "License Amendment") to its Collaboration and License Agreement with Kite Pharma, Inc., a Gilead Company ("Kite")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000119312523277504/0001193125-23-277504-index.htm
- Material Agreements
  Arcellx, Inc. amended Amended Standstill Agreement with Gilead Sciences, Inc. (effective 2023-11-15).
  - Action: amendment
  - Counterparty: Gilead Sciences, Inc.
  - Effective: 2023-11-15
  source text: Arcellx also amended and restated its standstill and stock restriction agreement, dated December 8, 2022, with Gilead (as amended, the "Amended Standstill Agreement")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000119312523277504/0001193125-23-277504-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.